Cardlytics
CDLX
51 hedge funds and large institutions have $141M invested in Cardlytics in 2018 Q1 according to their latest regulatory filings, with 51 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
4.87% more ownership
Funds ownership: 0% → 4.87% (+4.9%)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $695K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVMCV
Polaris Venture Management Co V
Boston,
Massachusetts
|
+$44.6M |
| 2 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
+$25.5M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$24.3M |
| 4 |
Jennison Associates
New York
|
+$13.7M |
| 5 |
VOYA Investment Management
Atlanta,
Georgia
|
+$8.03M |
Top Sellers
CDLX Hedge Fund Activity: Q1 2018 in Review
51 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Cardlytics (CDLX) for Q1 2018, worth a combined $141M.
Buyers outnumbered sellers: 51 funds opened new CDLX positions and 0 closed out — a net gain of 51 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Polaris Venture Management Co V, opening a new position worth an estimated $44.6M.
- 51 institutional investors held Cardlytics (CDLX) as of Q1 2018, up from 0 in Q4 2017.
- Funds reported $141M of Cardlytics stock for Q1 2018.
- 51 funds opened new Cardlytics positions in Q1 2018 and 0 closed out, a net change of +51 holders.
- The largest Cardlytics buyer in Q1 2018 was Polaris Venture Management Co V, an estimated $44.6M added.
Based on aggregated 13F filings for Q1 2018.